M arijuana has been used for medicinal purposes for more than 4,000 years. 1 There are numerous reports of ancient cultures burning marijuana and inhaling the smoke from this plant as an analgesic for crude surgeries, to treat headaches, and for other therapeutic and ceremonial purposes. 2 The marijuana plant originated in western and central Asia, but has since been cultivated and grown throughout many parts of the world. 2 Medical applications of marijuana became well-documented during the 19th century when European physicians extolled its therapeutic benefits for reducing anxiety and treating migraines and myriad other conditions. 2 Marijuana also was used extensively as a medical treatment in the United States well into the 20th century. 3 In 1937, however, the US government put severe financial and legal restrictions on the use of marijuana as a therapeutic agent, thereby reducing the availability of this plant for medical reasons. 1 The use of marijuana as a medication was further restricted in 1970, when it was classified as a schedule I controlled substance. 2, 3 Schedule I drugs are regarded as having a high abuse potential, no currently accepted medical use in the United States, and lack of an adequate level of safety (Tab. 1). Hence, this classification virtually abolished marijuana as a medicinal agent and severely restricted any research into its potential clinical benefits. It is difficult, for example, to perform well-controlled clinical trials on a substance when the government has determined that the substance has no clinical applications. 4, 5 There have been appeals from many agencies, political leaders, and advocate groups that marijuana be reclassified, perhaps as a schedule II drug. 3 The US Drug Enforcement Administration, however, recently reconfirmed that marijuana will remain a schedule I controlled substance, thus maintaining restrictions on the research and clinical indications of this drug.
Nonetheless, several changes occurred over the last 2 decades that rekindled the possibility of using marijuana legally for various medical conditions. These changes are complex, but basically involve the decriminalization of marijuana possession in many states, emerging evidence from case reports and anecdotal studies on the beneficial effects of marijuana, and the discovery that the body has an endogenous system that produces and responds to the chemicals found in marijuana. 1, 2 At the time of this writing, approximately half of the states in the United States have some form of medical marijuana. Certain beneficial effects are likewise synergistic with conditions seen commonly in physical therapist practice, including the treatment of pain, inflammation, and muscle hyperexcitability. Hence, many physical therapists are already working with patients who are using medical marijuana. In addition, clinicians are often consulted by their patients about whether marijuana might complement their physical rehabilitation or serve as an alternative pharmacological method for treating their condition.
The purpose of this perspective article is to review the current status of medical marijuana. The clinical pharmacology of marijuana will be addressed first, focusing on the active compounds (cannabinoids) that cause the positive and negative effects associated with marijuana. Potential clinical applications of marijuana will be addressed briefly, followed by adverse effects of this intervention. Finally, the relevance of medical marijuana to physical therapist practice will be addressed. This article is not intended to advocate for or against the use of medical marijuana, but to inform clinicians of current and future applications of this intervention, to enable clinicians to be a source of information for patients who have questions about medical marijuana, and to alert clinicians to possible adverse effects that could arise in patients using marijuana.
Marijuana and Related Cannabinoids
Marijuana comes from a pure or hybrid species of the plant genus Cannabis. There are 3 primary cannabis species: C sativa, C indica, and C ruderalis. 2, 6 These species have variable amounts of chemically active compounds called cannabinoids. 7 Marijuana usually refers to the C sativa species, which is high in cannabinoids that have psychoactive properties, whereas other species such as C ruderalis lack meaningful amounts The first is ⌬ 9 -tetrahydrocannabinol (THC), which tends to produce the psychotropic effects or "high" associated with smoking or ingesting marijuana. 2,4 The second compound, cannabidiol (CBD), does not have psychoactive properties and may actually balance or inhibit the psychotropic effects of THC. 4 Moreover, CBD may be more important than THC in producing therapeutic effects such as analgesia, decreased inflammation, decreased spasticity, and antiseizure effects. 9 The potential benefits of extracting CBD from other cannabinoids and ingesting these CBD extracts will be addressed later.
Marijuana tends to have high levels of THC and relatively low levels of CBD. 2 Likewise, cross-breeding and hybridization of marijuana plants have created myriad strains that have variable levels of THC and other psychoactive cannabinoids. 6 These strains purportedly can produce various physical and behavioral effects, depending on cultivation of the plant.
Methods of Drug Delivery
Various methods for administering cannabinoids and their relative effect times are summarized in Table 2 . Burning the marijuana plant causes combustion that releases the cannabinoid substances into a volatile mixture that is introduced into the lungs via smoke and absorbed though the alveolar membrane and into the pulmonary circulation. 10 These substances reach the systemic circulation, where they readily cross the blood-brain barrier and exert direct effects on the central nervous system and indirect effects on other organs and organ systems (heart, circulation, gastrointestinal [GI] tract) that are mediated primarily though the autonomic nervous system. Positive and negative effects on the central nervous system (CNS) and other organs will be addressed later.
Marijuana smoke can, of course, expose the pulmonary endothelium to hot, dry air that contains harmful products such as tar, pesticides, biological contaminants (bacteria, fungi), heavy metals, and other toxins that may have been incorporated into the plant during cultivation. 11 An alternative method of inhalation is vaporization, where the plant leaves are heated to a point just below combustion. 10 This action purportedly releases the cannabinoids into a vapor form without actually producing smoke that may damage the respiratory tract. 10 Marijuana also can be ingested orally by incorporating parts of the plant into teas or various baked goods such as cookies, brownies, and other edible products. 2, 12 Likewise, extracts from the plant can be used to produce an oil that is mixed into butters or other orally consumable products such as lozenges or candy-like products. Alternatively, the extract can be placed in a spray form or tincture that is applied to the oral mucosal membranes and absorbed through those membranes and into the systemic circulation, where it will ultimately reach the CNS. 13 Each method of delivery described above has benefits and drawbacks. Smoking or vaporizing marijuana produces rapid effects, where patients may begin to feel cannabinoid effects within a few minutes (Tab. 2). 10 This form of administration also is relatively easy to titrate because patients can wait after 1 or 2 inhalations to see if they are achieving a desired effect before taking additional inhalations of the drug. 10 As indicated above, smoking can produce harmful effects on the pulmonary structures, especially if there is preexisting lung disease (asthma, chronic obstructive pulmonary disease). Perhaps an even greater concern is the purity and content of the plant-based forms of the drug. The actual dosage of THC and other cannabinoids may be highly variable, depending on the strain and source of the marijuana plant. 11
Oral, edible forms of marijuana are convenient and easily administered, but are highly variable in terms of their effects (Tab. 2). 4,12 The actual amount and type of cannabinoids in edible marijuana can vary greatly from product to product. Moreover, there is a relatively long delay between when the product is ingested and when the patient experiences drug onset and peak drug effects. 4 Orally administered drugs must be absorbed from the GI tract and must undergo firstpass metabolism in the liver. That is, cannabinoids absorbed from the stomach and small intestine must first pass through the liver, where they are metab- -tetrahydrocannabinol (THC) products and plant extracts that are available as prescription drugs are listed in Table 3 .
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Although there are approximately 100 cannabinoids associated with the cannabis species, 2 cannabinoid substances have been studied extensively. 2, 4 The first is ∆
9
-tetrahydrocannabinol (THC), which tends to produce the psychotropic effects or "high" associated with smoking or ingesting marijuana. 2, 4 The second compound, cannabidiol (CBD), does not have psychoactive properties and may actually balance or inhibit the psychotropic effects of THC. 4 Moreover, CBD may be more important than THC in producing therapeutic effects such as analgesia, decreased inflammation, decreased spasticity, and antiseizure effects. 9 The potential benefits of extracting CBD from other cannabinoids and ingesting these CBD extracts will be addressed later.
olized to some extent before reaching the systemic circulation and CNS. Many variables, such as presence of food in the GI tract, GI blood flow, and hepatic function, therefore, influence when meaningful amounts of the drug reach the systemic circulation and ultimately the CNS. 4 As a result, it may be more difficult for patients to judge how much of the edible product to consume. Many anecdotal reports describe how people consume part of an edible product, but feel that "nothing is happening." 12 They then ingest more or the remainder of the product, which ultimately causes excessive or untoward psychotropic side effects, respiratory depression, and other adverse reactions. 14 Likewise, children may ingest edible products in the form of cookies, brownies, and candies, thus increasing the chance of accidental poisoning from these products. 14, 15 Oral mucosal sprays or tinctures known as nabiximols have been developed that contain the 2 primary cannabinoids (THC and CBD) (Tab. 3). 2,16 By using the oromucosal route, these products offer certain advantages over inhalation or oral ingestion. Onset is variable from person to person, but is still fairly rapid (usually within 10 -15 minutes). The dose can be controlled relatively well by administering a specific number of sprays or drops of tincture. 10 The oromucosal route also avoids the first-pass effect because the drug is absorbed through the mucosal membranes and into the systemic circulation before passing through the liver. The amount of the active substances in oromucosal products also may be more predictable, provided that these products are manufactured correctly, with adequate quality control of the product.
An oral spray form of nabiximols that contains equal amounts of THC and CBD is marketed under the trade name Sativex (GW Pharmaceuticals, Cambridge, United Kingdom) as a prescription drug in the United Kingdom, Canada, and other countries (Tab. 3). 13 Where available, this agent is used primarily to treat people with neuropathic pain and spasticity due to multiple sclerosis. 10, 16 At the time of this writing, this product and similar nabiximols are not yet available as prescription drugs in the United States.
Prescription Products
Marijuana's primary psychoactive component, THC, was first isolated in 1964. 3 Isolating this compound led to the development of oral formulations that contain synthetic compounds that are pharmacologically similar to THC. 17 These formulations provide a method for administering a known amount of synthetic THC that it is hoped will provide predictable effects because the dosage and pharmacokinetic variables (half-life, clearance) have been established during clinical trials. That is, patients can take a pill or capsule containing synthetic THC much in the same way as they take other prescription medications.
To date, 2 synthetic compounds that mimic THC have received Federal Drug Administration (FDA) approval and are used to treat specific conditions (Tab. 3). 17 The first product, dronabinol (Marinol, AbbVie Inc, North Chicago, Illinois), received FDA approval in 1985 and is indicated as an appetite stimulant to 2 There may be an important balance between the effects of THC and other cannabinoids such as CBD that influence the clinical effects of these compounds. Hence, studies that attempt to compare the beneficial effects of THC products with medical marijuana may fail to account for how various cannabinoids interact with each other when treating specific conditions. Likewise, it is curious why THC was the primary cannabinoid that was developed as a prescription agent in the United States. This compound clearly produces the primary psychotropic effects rather than potential nonpsychotropic medical benefits associated with medical marijuana. 9 It would seem more logical to develop agents that contain CBD because this cannabinoid may be responsible for producing analgesia, muscle relaxation, decreased seizures, and other beneficial effects, with little or no psychotropic effects. 9 Indeed, products containing only CBD have been developed, and a CBD formulation known as Epidiolex (GW Pharmaceuticals) is available on a limited basis for treating certain forms of drug-resistant epilepsy in the United States (Tab. 3). As indicated earlier, nabiximols such as Sativex that contain THC and CBD also are available in other countries as a possible way to achieve beneficial effects without overt psychotropic effects. Nabiximols are currently in phase 3 clinical trials in the United States, and these products and products containing only CBD may be available as prescription agents in the United States in the near future. Again, however, it seems strange that drug development has focused on THC products rather than products containing CBD. Even though both compounds were isolated around the same time (1964), efforts to develop CBD formulations have lagged well behind the development of THC drugs.
Clinical Applications of Medical Marijuana and Cannabinoids
Medical marijuana has been used to manage a diverse group of clinical conditions. 18, 19 In particular, plant-based cannabinoids have long been advocated as a method for treating CINV, 20,21 and their appetite-stimulating effects may help increase nutrient intake in patients with muscle wasting in conditions such as AIDS. 22 Cannabinoids have likewise been reported to reduce intraocular pressure in patients with glaucoma, 23 and certain cannabinoids such as CBD may help decrease symptoms of psychosis and anxiety. 24, 25 Various cannabinoid compounds have been reported as useful in the treatment of seizure disorders, including certain forms of resistant epilepsy. 26,27 These compounds also have been used to treat other neurological conditions, including Tourette syndrome. 28 Marijuana and cannabinoids also have received particular attention as a potential way to treat various types of pain. 29 -31 They have been used alone or with other analgesics to treat cancerrelated pain, 7,32 and they may be helpful in other types of chronic pain, including fibromyalgia 33 and neuropathic pain related to diabetes mellitus. 34 Cannabinoids have been used to treat spasticity and reduce painful muscle contractions in people with multiple sclerosis. 7, 35 It has been suggested that these compounds may be useful in other conditions, including rheumatoid arthritis, osteoarthritis, and various other types of acute and chronic musculoskeletal pain. 36 -38 Despite their increased use in the many clinical conditions, the efficacy of medical marijuana in these conditions remains controversial. Whereas certain case studies and anecdotal reports often advocate the benefits of these compounds, larger well-controlled trials may not always substantiate the clinical outcomes. 18, 19, 34 This fact should not be surprising, however, when one considers all of the variables involved in establishing clinical effects of various cannabinoids. As mentioned earlier, cannabinoids can be administered in many different ways, which will certainly affect clinical responses. Smoking marijuana, for example, will deliver variable doses of cannabinoids, depending on how deeply the user inhales, the amount and ratio of THC to CBD, other constituents in the marijuana strain, and so forth. 4,10 Administering synthetic THC products (dronabinol, nabilone) can help standardize the dose, but it may be a mistake to compare these studies with those administering the extract from the whole marijuana plant. This would be like comparing the effects of smoked opium with a synthetic opioid such as fentanyl or oxycodone.
It is beyond the scope of this article to provide a detailed review of the evidence for or against the clinical effects of marijuana and cannabinoid drugs. Moreover, many other variables may make it difficult to compare the results of different studies or to perform a meaningful systematic review or meta-analysis on the effects of medical marijuana. In particular, severity of the condition, patient expectations, and prior use of other analgesics (including prior cannabis use) may substantially influence the patient's response to medical marijuana. 29, 34 Hence, many practitioners have adopted a "let the patient decide" strategy regarding the potential benefits of these compounds. Although the patient should certainly be aware of the possible side effects addressed in the next section, it might be necessary to judge the effects on an individual basis. Well-controlled clinical trials may help determine the efficacy in a group of patients with a specific disorder, but these studies cannot always account for individual patient characteristics and other variables that will influence the positive and negative effects on a specific patient. Hence, it seems incumMedical Marijuana bent on clinicians to work closely with the patient and his or her caregivers when trying to assess the effects of cannabinoids in that patient.
Adverse CNS Effects of Marijuana
Medical marijuana is associated with some well-known and predictable psychotropic effects. These effects include feelings of giddiness, increased perception, euphoria, and mood changes often described as "mellowing out." 4 These effects are, of course, often the desirable aspects of recreational marijuana use. On the other hand, some users may report unpleasant or frightening reactions, including confusion, hallucinations, panic reactions, paranoia, and acute psychotic effects. 4, 19 These psychotropic properties are highly variable from person to person and are influenced by many factors, such as the method of ingestion (smoking versus edible products), the strain of marijuana and related THC concentration, the person's prior use and experiences with cannabinoids, and the concomitant use of other drugs such as alcohol, opioids, and benzodiazepines. 2, 10 Medical marijuana also can cause shortterm impairments in cognition, memory, alertness, coordination, and balance. 11, 39 -41 Impairments in balance and coordination may increase the risk of falls and other accidents, especially in older adults or people with neuromusculoskeletal conditions. Likewise, marijuana will impair the ability to think and react quickly when driving a car and in other situations that might require quick mental and physical reactions (workplace, school). 42, 43 Again, the extent of these reactions varies greatly from person to person, but it is clear that users of medical marijuana should not operate a motor vehicle or engage in other activities that require quick reactions while experiencing the effects of this drug. 43 Although the acute CNS effects of marijuana are well known, there is considerable controversy about possible long-term adverse effects on CNS function. 39, 40 Much of this controversy arises from studies on heavy or habitual recreational marijuana smokers, and comparison with medical marijuana may be misleading. 44 As discussed earlier, there may be substantial differences in the composition of recreational marijuana compared with marijuana cultivated for medical use, as well as alternative forms for ingesting medical cannabinoid products (tablets, oromucosal sprays). Perhaps even more intriguing is the possibility that use of cannabinoids for medical conditions may have a different adverse profile because these drugs are being used for a specific reason (analgesia, antispasticity, antiemesis, and so forth). That is, cannabinoids may cause fewer or less problematic adverse effects because their beneficial effects are focused on treating a clinical problem rather than merely causing psychotropic effects. 45 This situation would be analogous to administering the correct dose of an approved opioid to manage physical pain in patients who do not have an addictive history compared with selfadministration of an illegal product such as heroin to achieve an opioid "high." The risk of certain adverse effects, including addiction, is certainly more acceptable when opioids are used appropriately in clinical situations compared with illicit opioid use. 46 Nonetheless, questions have been raised about the long-term CNS effects of medical marijuana. 47 There are concerns that marijuana use may cause cognitive impairments and that repeated, heavy use may lead to a cluster of symptoms known commonly as cannabis use disorder (CUD) (Appendix). 45 As indicated in the Appendix, CUD includes symptoms such as lack of motivation, decreased concentration, and loss of interest in other activities. Tolerance and dependence also are characteristics of CUD, indicating that marijuana does have addictive potential (Appendix). 48 Again, CUD has been documented primarily in recreational users, and the risk of this disorder in people who use medical marijuana for specific conditions remains to be fully determined. 49 Whether CUD occurs in specific patients will almost certainly be influenced by many factors, such as the type of cannabinoids ingested, dosage and duration of use, prior history of drug addiction, concomitant use of other drugs, and so forth.
In addition, some studies suggest that marijuana may increase the onset of symptoms of psychosis, depression, and other psychiatric disorders in susceptible individuals. 41, 50, 51 Children and adolescents may be especially susceptible to adverse effects such as depression, and there is considerable debate about the safety of certain cannabinoids such as THC on the developing CNS. 52, 53 Hence, there are reasonable concerns that long-term use of medical marijuana might affect certain CNS functions, especially related to mood and behavior. It is not clear, however, if these adverse effects are transient or if regular use can produce permanent changes in CNS structure and function. 2 Again, much of our current understanding of adverse CNS changes is based on heavy recreational users. Clearly, we need more research on how long-term use of specific medical marijuana and cannabinoid products exerts positive and negative effects on the CNS in specific patient populations.
Finally, marijuana has been described as a "gateway" drug that could lead to increased drug-seeking behavior and abuse of other drugs. 54 This gateway hypothesis is based on the idea that marijuana might cause changes in the brain that ultimately increase the likelihood that an individual will use other, potentially more dangerous drugs. 55 Although the majority of occasional recreational marijuana users do not progress to "harder" drugs, regular and heavy marijuana use is associated with increased consumption of other licit and illicit drugs in certain individuals. 55, 56 It is unclear, however, if early marijuana use actually causes individuals to seek or become addicted to other drugs. 56, 57 That is, it is difficult to determine if marijuana is the sole reason that an individual will ultimately seek other drugs. Drug abuse and addiction are certainly complex phenomena, with social, genetic, mental health, and other factors also influencing whether an individual will eventually use other drugs. 55, 58 The gateway hypothesis also has been attributed primarily to heavy recreational marijuana use, and it is not clear if use of medical marijuana or specific cannabinoids
Medical Marijuana
(CBD) will invariably invoke drugseeking behaviors. Hence, the idea that marijuana is a gateway drug is certainly a reason for concern, but it is not clear at the present time if medical marijuana will lead to increased use of other drugs. Nonetheless, this intervention should be used cautiously in certain individuals and perhaps avoided altogether in any people who have specific risk factors, such as a history of addiction (including nicotine or alcohol addiction), or mental health issues, such as depression or psychosis. 55,57
Adverse Effects of Marijuana on Peripheral Organs
Marijuana can cause acute effects on the cardiovascular system, including tachycardia, increased blood pressure, and increased myocardial oxygen demand. 59, 60 These effects are likely due to increased sympathetic nervous system activity and have obvious implications if patients are exercising when cannabinoids are active in their body. Indeed, marijuana is associated with decreased time to the onset of chest pain during exercise in patients with angina pectoris. 60 The risk of acute myocardial infarction due to coronary artery vasospasm may be elevated in susceptible individuals within an hour or so after smoking marijuana. 59 Marijuana also is associated with an increased risk of acute ischemic stroke, including an increased relative risk of stroke in users who were fairly young (25-34 years of age). 61 However, these effects on cardiovascular function have often been observed in recreational marijuana users, and it may not be appropriate to directly apply these results to patients using medical marijuana. Nonetheless, medical marijuana and specific cannabinoids such as THC and CBD should be used cautiously, or perhaps even avoided, in patients with a history of coronary heart disease and other cardiovascular problems. 59, 60 Smoking marijuana also can have obvious acute effects on pulmonary function. 62 In particular, short-term use may affect the vascular endothelium in the small airways, thus decreasing airflow in these airways. 63 It is not clear, however, if these effects are clinically meaningful during the short-term use of smoked medical marijuana in patients who do not have other pulmonary pathologies. Likewise, other inhalation techniques such as vaporizing may reduce this effect, and it seems unlikely that airway restrictions will be a problem when using noninhaled products such as edibles and oromucosal sprays. 62 Clearly, the larger concern for pulmonary health is in individuals who smoke marijuana heavily on a long-term basis. Extensive and repeated marijuana smoking will likely cause airway inflammation, airflow obstruction, and symptoms similar to excessive cigarette smoking (wheezing, cough, increased sputum). 64, 65 Regarding GI function, marijuana can cause nausea and vomiting in certain individuals, a condition known commonly as hyperemesis syndrome. 66, 67 This syndrome seems paradoxical considering that certain users ingest marijuana to help alleviate CINV and other conditions that cause GI upset. The reasons for hyperemesis are not well understood, but people who develop this problem often try to reduce these GI problems by taking hot baths. 66, 67 Again, it is not clear why hyperemesis occurs or why certain people are more susceptible to this problem.
Relevance to Physical Rehabilitation
Patients and their caregivers may approach physical therapists with questions about medical marijuana. This idea seems logical given that cannabinoids may have synergistic effects with various rehabilitation goals such as decreasing pain, inflammation, and spasticity. Physical therapists likewise play an important role in medication management, including their role in providing education about specific medications. Drug prescribing, however, remains outside the scope of practice for most physical therapists. Although some physical therapists in the US military can receive additional training and become credentialed to prescribe certain medications, 68 nonmilitary physical therapists cannot prescribe medications in the United States. Hence, physical therapists are not allowed to prescribe medical marijuana even if they practice in a state where these drugs are approved as prescription medications. In addition, it is probably unwise for physical therapists to advise their patients to use marijuana as a supplement even if these products are available for recreational purposes. The physical therapist may simply not be aware of medical issues that could cause negative effects when these drugs are used by specific patients or clients. Patients interested in possible use of medical marijuana should be referred to their physician for a full medical evaluation so that these products can be prescribed safely and effectively.
As is the case with other health care providers, physical therapists may need to serve as a source of information about the benefits and drawbacks of medical marijuana. 69 Again, the physical therapist will be providing education rather than directly suggesting that the patient use marijuana for clinical reasons. In particular, patients and their caregivers should know that medical marijuana is composed of many different pharmacologically active compounds and that there are many ways of administering these compounds. Patients may think that smoking the marijuana plant is the only way to self-administer these compounds, and they can be informed that there are several alternative strategies for ingesting marijuana or extracts from this plant.
Likewise, patients should know CBD and other components from the mixture of plant-based cannabinoids have been isolated and are being investigated as possible clinical strategies. As indicated earlier, clinical trials of products that contain only CBD or a mixture of CBD and THC are in progress, and these products may eventually be available as prescription drugs in the United States. Clinicians, therefore, should be aware that innovative drug strategies related to medical marijuana may reach the market and be ready to inform their patients of whether these new drugs may be helpful in treating the conditions seen commonly in their practices.
On the other hand, clinicians may already be working with patients using some form of medical marijuana. Clinicians should monitor the effects of these 
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Conclusion
Medical marijuana continues to gain acceptance as a complementary or alternative treatment for a variety of clinical disorders. Although there is still considerable controversy about whether medical marijuana is effective in specific conditions, anecdotal reports and case studies have generated interest in the use of this intervention in treating pain, inflammation, spasticity, and other problems seen commonly in physical therapist practice. Likewise, isolation of specific compounds (cannabinoids) from the marijuana plant have laid the groundwork for developing drugs that could provide medical benefits without the undesirable psychotropic effects commonly associated with marijuana. Clearly, there is a need for much more research in this area, and legalization and reclassification of marijuana as a medical intervention could allow such studies to emerge in the near future. In the meantime, physical therapists should be able to educate their patients about the current status of medical marijuana and direct their patients and their caregivers to physicians who can provide further information about this intervention. Likewise, clinicians must be aware of the potential side effects of medical marijuana and be vigilant for signs of excessive or inappropriate use of this intervention.
